mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. (Q51452386)
Jump to navigation
Jump to search
scientific article published on 28 September 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. |
scientific article published on 28 September 2016 |
Statements
1 reference
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. (English)
1 reference
Wenjun Wang
1 reference
Wei Bai
1 reference
Enxin Wang
1 reference
Yan Zhao
1 reference
Lei Liu
1 reference
Man Yang
1 reference
Hongwei Cai
1 reference
Dongdong Xia
1 reference
Lei Zhang
1 reference
Jing Niu
1 reference
Zhanxin Yin
1 reference
Zhuoli Zhang
1 reference
Daiming Fan
1 reference
Jielai Xia
1 reference
Guohong Han
1 reference
28 September 2016
1 reference
140
1 reference
2
1 reference
390-399
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference